Targeting human caseinolytic protease P (ClpP) as a novel therapeutic strategy in ovarian cancer

Targeting human caseinolytic protease P (ClpP) as a novel therapeutic strategy in ovarian cancer

Abstract Ovarian cancer (OC) is currently one of the most life‐threatening types of gynecological malignancy with limited treatment options and poor clinical outcomes. Human caseinolytic protease P (HsClpP) is located in the mitochondria and plays an important role in several tumors. Moreover, HsClp...

Full description

Bibliographic Details
Main Authors: Baozhu Luo, Jiangnan Zhang, Wenliang Qiao, Yuanzhen Zhou, Jiasheng Huang, Tao Yang, Youfu Luo
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:MedComm – Oncology
Subjects:
ATF4
human caseinolytic protease P
mitochondria dysfunction
ovarian cancer
SDHB
small molecule drugs
Online Access:https://doi.org/10.1002/mog2.14

Internet

https://doi.org/10.1002/mog2.14

Similar Items